{"id":"moxifloxacin-hydrochloride-ophthalmic","safety":{"commonSideEffects":[{"rate":null,"effect":"Conjunctival irritation"},{"rate":null,"effect":"Eye discomfort"},{"rate":null,"effect":"Ocular hyperemia"},{"rate":null,"effect":"Taste perversion"},{"rate":null,"effect":"Corneal staining"}]},"_chembl":{"chemblId":"CHEMBL1200735","moleculeType":"Small molecule","molecularWeight":"437.90"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As a broad-spectrum fluoroquinolone, moxifloxacin works by binding to and inhibiting bacterial DNA gyrase (in gram-negative bacteria) and topoisomerase IV (in gram-positive bacteria), enzymes essential for DNA replication and repair. This dual mechanism results in rapid bactericidal activity against a wide range of gram-positive and gram-negative bacteria, as well as atypical organisms. When formulated as an ophthalmic solution, it achieves high local concentrations in ocular tissues to treat bacterial infections of the eye.","oneSentence":"Moxifloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription in susceptible microorganisms.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:22:06.057Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Bacterial conjunctivitis"},{"name":"Bacterial keratitis"},{"name":"Bacterial corneal ulcer"},{"name":"Post-operative ocular infections"}]},"trialDetails":[{"nctId":"NCT07225699","phase":"NA","title":"IN PATIENTS WITH CORNEAL ABRASIONS TREATED WITH COLLAGEN CORNEAL SHIELDS IN THE EMERGENCY DEPARTMENT SETTING","status":"NOT_YET_RECRUITING","sponsor":"Milton S. Hershey Medical Center","startDate":"2026-05-15","conditions":"Corneal Abrasions","enrollment":60},{"nctId":"NCT07394257","phase":"NA","title":"Intrastromal Moxifloxacin as an Adjunctive Therapy in Recalcitrant Bacterial Keratitis","status":"RECRUITING","sponsor":"Minia University","startDate":"2025-10-01","conditions":"Bacterial Keratitis, Recalcitrant Infectious Keratitis, Corneal Ulcer","enrollment":60},{"nctId":"NCT05110001","phase":"PHASE3","title":"Rose Bengal Electromagnetic Activation With Green Light for Infection Reduction","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2022-08-03","conditions":"Acanthamoeba Keratitis, Fungal Keratitis","enrollment":330},{"nctId":"NCT07305987","phase":"PHASE3","title":"PRO-232 in Patients Subjected to Cataract Surgery","status":"RECRUITING","sponsor":"Laboratorios Sophia S.A de C.V.","startDate":"2025-10-27","conditions":"Cataract Extraction","enrollment":134},{"nctId":"NCT06271772","phase":"PHASE3","title":"Rose Bengal Electromagnetic Activation With Green Light for Infection Reduction II","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of California, San Francisco","startDate":"2024-07-01","conditions":"Bacterial Keratitis","enrollment":60},{"nctId":"NCT06352541","phase":"PHASE1","title":"Study Evaluating PRO-232 an Ophthalmic Solution Compared to Placebo.","status":"NOT_YET_RECRUITING","sponsor":"Laboratorios Sophia S.A de C.V.","startDate":"2025-09-30","conditions":"Healthy","enrollment":28},{"nctId":"NCT05331664","phase":"PHASE4","title":"Dropless Pars Plana Vitrectomy Study","status":"RECRUITING","sponsor":"Massachusetts Eye and Ear Infirmary","startDate":"2022-07-25","conditions":"Rhegmatogenous Retinal Detachment","enrollment":168},{"nctId":"NCT06363292","phase":"PHASE1","title":"Study to Evaluate the Safety and Tolerability of PRO-231 Versus VIGAMOXI® on the Ocular Surface of Healthy Subjects","status":"COMPLETED","sponsor":"Laboratorios Sophia S.A de C.V.","startDate":"2024-01-30","conditions":"Ophthalmological Agent Toxicity, Bacterial Conjunctivitis","enrollment":37},{"nctId":"NCT06785090","phase":"PHASE4","title":"Effects of Bromfenac on Macular Thickness After Phacoemulsification Surgery","status":"COMPLETED","sponsor":"Inas Abd","startDate":"2023-05-01","conditions":"Cataract, Cystoid Macular Edema After Phacoemulsification","enrollment":87},{"nctId":"NCT04750655","phase":"PHASE4","title":"Antibiotic Resistance In Eye Surgeries","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2021-03-01","conditions":"Antibiotic Resistance, Ocular Surface Microbiome, Gut Resistome","enrollment":108},{"nctId":"NCT06879301","phase":"EARLY_PHASE1","title":"Effectiveness of Intravitreal Injection of Aflibercept 8 mg in Resistant Diabetic Macular Edema, Retinal Vein Occlusion and Myopic Choroidal Neovascularisation Patients","status":"NOT_YET_RECRUITING","sponsor":"Tanta University","startDate":"2025-10-19","conditions":"Diabetic Macular Edema (DME), Retinal Vein Occlusion (RVO), Myopic Choroidal Neovascularisation","enrollment":60},{"nctId":"NCT04097730","phase":"PHASE3","title":"Steroids and Cross-linking for Ulcer Treatment","status":"COMPLETED","sponsor":"Thomas M. Lietman","startDate":"2020-09-24","conditions":"Keratitis Bacterial","enrollment":280},{"nctId":"NCT06681688","phase":"PHASE1, PHASE2","title":"Study of Complication Rates in Cataract Surgery Patients Treated With Combined Pre-operative NSAID, OMIDRIA, and Subconjunctival Triamcinolone Acetonide Compared With Peri-operative SOC","status":"RECRUITING","sponsor":"Inder Paul Singh, M.D.","startDate":"2024-07-10","conditions":"Cataract","enrollment":94},{"nctId":"NCT06427629","phase":"NA","title":"Investigator-initiated Clinical Trial to Observe Conjunctival Goblet Cell Using an Anterior Segment Imaging Device","status":"RECRUITING","sponsor":"Seoul National University Hospital","startDate":"2024-06-12","conditions":"Ocular Surface Disease","enrollment":148},{"nctId":"NCT05413980","phase":"","title":"Effectiveness and Safety of 0.5% Moxifloxacin Hydrochloride Ophthalmic Solution in Perioperative Sterilization in Patients Undergoing Ophthalmic Surgery","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2024-01-27","conditions":"Post Operative Endophthalmitis","enrollment":102},{"nctId":"NCT05655689","phase":"","title":"The Antibiogram and Outcomes of Antimicrobial Regimens in Microbial Keratitis: A Prospective Cohort Study","status":"COMPLETED","sponsor":"Alexandria University","startDate":"2021-12-31","conditions":"Bacterial Keratitis, Fungal Keratitis, Mixed Bacterial and Fungal Keratitis","enrollment":123},{"nctId":"NCT05741632","phase":"PHASE1","title":"Safety Profile Comparison of Undiluted Intracameral Moxifloxacin vs. Levofloxacin in Cataract Surgery","status":"COMPLETED","sponsor":"Indonesia University","startDate":"2023-02-01","conditions":"Cataract","enrollment":68},{"nctId":"NCT04204122","phase":"PHASE2","title":"Vigamox Treatment for Ocular Graft-Versus-Host Disease","status":"WITHDRAWN","sponsor":"Washington University School of Medicine","startDate":"2020-06-15","conditions":"Ocular Graft-versus-host Disease","enrollment":""},{"nctId":"NCT04521140","phase":"PHASE4","title":"Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Corneal Transplant Surgery","status":"COMPLETED","sponsor":"Nicole Fram M.D.","startDate":"2020-10-16","conditions":"Corneal Edema, Corneal Defect, Corneal Transplant","enrollment":36},{"nctId":"NCT03634852","phase":"PHASE4","title":"A Two Chemoprophylaxis Approaches After Phacoemulsification Surgery","status":"COMPLETED","sponsor":"Suzan A Rattan","startDate":"2016-10-01","conditions":"Endophthalmitis Postoperative","enrollment":1000},{"nctId":"NCT05665270","phase":"PHASE4","title":"A Study for Post op Inflammation After Cataract Surgery","status":"UNKNOWN","sponsor":"Wyse Eyecare","startDate":"2023-01-30","conditions":"Cataract","enrollment":40},{"nctId":"NCT05255107","phase":"PHASE2, PHASE3","title":"Safety and Effectiveness of the PXL Platinum 330 System With Riboflavin Solution for Previously Untreated Corneal Ulcers","status":"UNKNOWN","sponsor":"Peschke GmbH","startDate":"2022-03-14","conditions":"Keratitis, Corneal Ulcer","enrollment":468},{"nctId":"NCT05428683","phase":"NA","title":"Intravitreal Triamcinolone and Moxifloxacin Injection After Cataract Surgery","status":"COMPLETED","sponsor":"Emad Abdel Aal Saliem","startDate":"2020-12-03","conditions":"Pharmacological Action","enrollment":84},{"nctId":"NCT05331859","phase":"PHASE1","title":"Topical Insulin Versus Autologous Serum After Corneal Surgeries","status":"UNKNOWN","sponsor":"Benha University","startDate":"2022-05","conditions":"Corneal Epithelial Wound","enrollment":250},{"nctId":"NCT03580473","phase":"PHASE2","title":"Efficacy and Safety of Saturno IIB Association on the Control of Ocular Inflammation Post-phacoemulsification","status":"COMPLETED","sponsor":"EMS","startDate":"2020-02-27","conditions":"Ocular Inflammation, Cataract","enrollment":118},{"nctId":"NCT05162625","phase":"PHASE2","title":"Safety and Efficacy of Topical Moxifloxacin for Prevention of Post-Traumatic Endophthalmitis: Randomized Controlled Clinical Trial","status":"UNKNOWN","sponsor":"University of Campinas, Brazil","startDate":"2021-12-10","conditions":"Endophthalmitis, Open Globe Injury, Moxifloxacin","enrollment":100},{"nctId":"NCT05079854","phase":"PHASE4","title":"Use Of Intracameral Moxifloxacin For Prophylaxis Of Open Globe Endophthalmitis","status":"UNKNOWN","sponsor":"Federal University of São Paulo","startDate":"2021-10-01","conditions":"Endophthalmitis, Trauma, Corneal","enrollment":100},{"nctId":"NCT03640650","phase":"PHASE4","title":"Economic Impact of Dropless Therapy Versus Usual Care for Cataract Surgery: A Real-World Study.","status":"TERMINATED","sponsor":"PeriPharm","startDate":"2018-08-15","conditions":"Cataract Surgery","enrollment":80},{"nctId":"NCT01296191","phase":"PHASE4","title":"Aqueous Absorption and Pharmacokinetics of Besivance Versus VIGAMOX in Patients Undergoing Phacoemulsification","status":"COMPLETED","sponsor":"Frank A. Bucci, Jr., M.D.","startDate":"2011-05","conditions":"Cataracts","enrollment":120},{"nctId":"NCT04273282","phase":"PHASE4","title":"A Prospective Clinical Study Evaluating Dexycu vs Prednisolone Acetate 1%","status":"COMPLETED","sponsor":"Research Insight LLC","startDate":"2019-12-16","conditions":"Cataract","enrollment":31},{"nctId":"NCT01296542","phase":"PHASE4","title":"A Comparison of Prophylactic Antibacterial Efficacy of Besivance vs. VIGAMOX Prior to Cataract Surgery","status":"COMPLETED","sponsor":"Bucci Laser Vision Institute","startDate":"2011-05","conditions":"Cataracts","enrollment":60},{"nctId":"NCT02717871","phase":"PHASE3","title":"Swiss PACK-CXL Multicenter Trial for the Treatment of Infectious Keratitis","status":"COMPLETED","sponsor":"University Hospital, Geneva","startDate":"2016-03","conditions":"Keratitis; Infectious Disease (Manifestation)","enrollment":35},{"nctId":"NCT04212429","phase":"PHASE1, PHASE2","title":"The Clinical Safety of Levofloxacin 1.5% vs Topical Moxifloxacin 0.5%","status":"UNKNOWN","sponsor":"National University of Malaysia","startDate":"2019-09-23","conditions":"Endophthalmitis Postoperative","enrollment":128},{"nctId":"NCT04214821","phase":"PHASE1, PHASE2","title":"The Pharmacokinetics of Topical Levofloxacin 1.5% vs Topical Moxifloxacin 0.5%","status":"UNKNOWN","sponsor":"National University of Malaysia","startDate":"2019-09-23","conditions":"Endophthalmitis","enrollment":128},{"nctId":"NCT04403334","phase":"PHASE4","title":"Postoperative Safety Outcomes of Intraoperative Intracameral Preservative-Free Moxifloxacin Versus Levofloxacin","status":"COMPLETED","sponsor":"Peregrine Eye and Laser Institute","startDate":"2018-01-02","conditions":"Cataract Senile, Endophthalmitis, Antibiotic Side Effect","enrollment":114},{"nctId":"NCT04205916","phase":"PHASE4","title":"A Trial Evaluating Patient Preference of Dropless vs Drops Post Cataract Surgery","status":"RECRUITING","sponsor":"Ophthalmic Consultants of Long Island","startDate":"2019-11-04","conditions":"Patient Preference","enrollment":50},{"nctId":"NCT00690313","phase":"PHASE4","title":"Dosage Study for Vigamox Eye Drops Prior to Intravitreal Injections","status":"COMPLETED","sponsor":"Illinois Retina Associates","startDate":"2008-08","conditions":"Intravitreal Injection Patients","enrollment":22},{"nctId":"NCT02980523","phase":"PHASE2","title":"Safety and Efficacy of PRO-157 vs Moxifloxacin vs Gatifloxacin in Patients With Bacterial Conjunctivitis (Pazufloxacin)","status":"COMPLETED","sponsor":"Laboratorios Sophia S.A de C.V.","startDate":"2015-03","conditions":"Bacterial Conjunctivitis","enrollment":150},{"nctId":"NCT00324168","phase":"PHASE4","title":"Steroids for Corneal Ulcers Trial","status":"COMPLETED","sponsor":"Thomas M. Lietman","startDate":"2006-09","conditions":"Corneal Ulcer, Eye Infections, Bacterial","enrollment":500},{"nctId":"NCT02515045","phase":"PHASE4","title":"Dropless vs. Standard Drops Contralateral Eye Study","status":"COMPLETED","sponsor":"Carolina Eyecare Physicians, LLC","startDate":"2015-01","conditions":"Cataract","enrollment":59},{"nctId":"NCT00759148","phase":"PHASE3","title":"Moxifloxacin AF Ophthalmic Solution for Treatment of Bacterial Conjunctivitis","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2008-10","conditions":"Bacterial Conjunctivitis","enrollment":1179},{"nctId":"NCT00924729","phase":"PHASE4","title":"Study of Ocular Penetration of Topically Administered Fluoroquinolones","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2009-09","conditions":"Cataract Extraction","enrollment":50},{"nctId":"NCT00332293","phase":"PHASE3","title":"AL-15469A for the Treatment of Bacterial Conjunctivitis","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2006-05","conditions":"Bacterial Conjunctivitis","enrollment":695},{"nctId":"NCT02865876","phase":"PHASE3","title":"Effectiveness of Corneal Accelerated Crosslinking for Infectious Keratitis","status":"UNKNOWN","sponsor":"Instituto de Oftalmología Fundación Conde de Valenciana","startDate":"2015-06","conditions":"Keratitis","enrollment":264},{"nctId":"NCT02816905","phase":"PHASE4","title":"Ocular-hypertensive Response to Topical Steroids in Children After Bilateral Strabismus Surgery","status":"COMPLETED","sponsor":"Cairo University","startDate":"2015-10","conditions":"Intraocular Pressure","enrollment":40},{"nctId":"NCT00581542","phase":"PHASE4","title":"Moxifloxacin vs. Polytrim for Conjunctivitis","status":"COMPLETED","sponsor":"University of Rochester","startDate":"2007-03","conditions":"Conjunctivitis","enrollment":124},{"nctId":"NCT02625467","phase":"PHASE1","title":"Treatment of Keratoconus With PALK Versus PK","status":"COMPLETED","sponsor":"Instituto de Oftalmología Fundación Conde de Valenciana","startDate":"2013-06","conditions":"Keratoconus","enrollment":28},{"nctId":"NCT01928693","phase":"PHASE2","title":"A Comparison of Three Fluoroquinolone Topical Eyedrops in the Treatment of Infectious Corneal Ulcers.","status":"TERMINATED","sponsor":"Cornea Consultants Of Nashville","startDate":"2013-07","conditions":"Corneal Ulcers","enrollment":2},{"nctId":"NCT01573910","phase":"PHASE3","title":"An Evaluation of the Safety and Efficacy of Moxifloxacin Ophthalmic Solution 0.5% ((VIGAMOX®) Versus Ofloxacin Ophthalmic Solution 0.3% in the Treatment of Bacterial Conjunctivitis in Chinese Patients","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2012-05","conditions":"Bacterial Conjunctivitis","enrollment":985},{"nctId":"NCT00348348","phase":"PHASE3","title":"A Study to Investigate the Safety and Efficacy of BOL-303224 in the Treatment of Bacterial Conjunctivitis","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2006-06","conditions":"Acute Bacterial Conjunctivitis","enrollment":1161},{"nctId":"NCT01515826","phase":"PHASE3","title":"VIGADEXA Gel Compared to VIGADEXA Solution Following Cataract Surgery","status":"WITHDRAWN","sponsor":"Alcon Research","startDate":"2014-03","conditions":"Cataracts","enrollment":""},{"nctId":"NCT01859702","phase":"PHASE4","title":"Pharmacokinetic Evaluation of Moxifloxacin in Vigadexa® in Aqueous Humor Samples Following Preoperative Antibiotic/Steroid Dosing in Cataract Surgery Patients","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2012-04","conditions":"Cataract","enrollment":36},{"nctId":"NCT00414011","phase":"NA","title":"Comparison of the Effect of 4th Generation Fluoroquinolones, Gatifloxacin and Moxifloxacin, on Epithelial Healing Following Photorefractive Keratectomy (PRK), A Substudy of: Initial Evaluation of Excimer Laser Keratorefractive Surgery in U.S. Army Personnel (WU # 2335-99)","status":"COMPLETED","sponsor":"Walter Reed Army Medical Center","startDate":"","conditions":"Epithelium, Corneal","enrollment":40},{"nctId":"NCT00579020","phase":"PHASE2","title":"A Phase II Study of Moxidex Ophthalmic Solution for Treatment of Marginal Corneal Infiltrates","status":"TERMINATED","sponsor":"Alcon Research","startDate":"2007-12","conditions":"Corneal Infiltrates","enrollment":144},{"nctId":"NCT00312338","phase":"PHASE4","title":"Topical Treatment of Bacterial Conjunctivitis and Its Effect on Microbial Flora","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2006-06","conditions":"Bacterial Conjunctivitis","enrollment":137},{"nctId":"NCT00840580","phase":"PHASE4","title":"Effect on Wound Healing of Vigamox Versus Cravit","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2009-01","conditions":"Cataract Extraction","enrollment":79},{"nctId":"NCT01577342","phase":"NA","title":"Determining the Effect of Antibiotic Drop Prophylaxis on the Conjunctival Flora","status":"COMPLETED","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","startDate":"2010-11","conditions":"Age-Related Macular Degeneration","enrollment":56},{"nctId":"NCT00874887","phase":"PHASE4","title":"A Clinical Study to Evaluate if Benzalkonium Chloride (BAK) in a Quinolone Eyedrop Reduces the Likelihood of Developing Resistant Organisms","status":"COMPLETED","sponsor":"Allergan","startDate":"2009-03","conditions":"Anti-biotic Resistance","enrollment":66},{"nctId":"NCT00824070","phase":"PHASE1","title":"Assessment of the Concentrations of Besifloxacin, Moxifloxacin, or Gatifloxacin in the Aqueous Humor of Subjects","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2009-02","conditions":"Cataract Extraction","enrollment":105},{"nctId":"NCT00905762","phase":"PHASE1","title":"Concentration of Besifloxacin, Gatifloxacin, and Moxifloxacin in Human Conjunctiva After Topical Instillation","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2009-03","conditions":"Healthy","enrollment":119},{"nctId":"NCT01455233","phase":"PHASE4","title":"2-Site Safety Study of Besivance Versus Vigamox Prophylactically in Routine Cataract Surgery","status":"COMPLETED","sponsor":"Ophthalmology Consultants, Ltd.","startDate":"2010-09","conditions":"Corneal Health, Cataract Surgery","enrollment":60},{"nctId":"NCT00564447","phase":"PHASE4","title":"Study of AzaSite (Azithromycin) Versus Vigamox in the Conjunctiva of Healthy Volunteers","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-12","conditions":"Bacterial Infections, Eye Infections","enrollment":48},{"nctId":"NCT00575380","phase":"PHASE4","title":"Study of AzaSite Versus Vigamox Concentrations in the Conjunctiva and Aqueous Humor in Subjects Undergoing Routine Cataract Surgery","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-12","conditions":"Bacterial Infections, Eye Infections, Cataract Extraction","enrollment":116},{"nctId":"NCT00575367","phase":"PHASE4","title":"Study of AzaSite Versus Vigamox in the Tears of Healthy Volunteers","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-03","conditions":"Bacterial Infections, Eye Infections","enrollment":37},{"nctId":"NCT00464438","phase":"PHASE4","title":"A Study to Evaluate the Safety and Efficacy of Gatifloxacin for the Treatment of Bacterial Conjunctivitis","status":"COMPLETED","sponsor":"Allergan","startDate":"2007-06","conditions":"Bacterial Conjunctivitis","enrollment":171},{"nctId":"NCT00732446","phase":"PHASE3","title":"Safety/Efficacy of Antibiotic Steroid Combination in Treatment of Blepharitis and/or Keratitis and/or Conjunctivitis","status":"COMPLETED","sponsor":"Federal University of São Paulo","startDate":"2008-08","conditions":"Blepharitis, Conjunctivitis, Keratitis","enrollment":100},{"nctId":"NCT00798577","phase":"PHASE4","title":"Study of the Progression of Bacterial Conjunctivitis Symptoms Upon Antibiotic Treatment","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2008-10","conditions":"Bacterial Conjunctivitis","enrollment":24},{"nctId":"NCT00870103","phase":"PHASE4","title":"Study of Efficacy and Safety of Vigadexa in Treating Inflammation and Infection Post-cataract Surgery","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2008-09","conditions":"Cataract","enrollment":64},{"nctId":"NCT00764582","phase":"PHASE4","title":"Ocular Penetration of 1.5% Levofloxacin and 0.5% Moxifloxacin During Corneal Transplant Surgery","status":"TERMINATED","sponsor":"Santen Inc.","startDate":"2008-09","conditions":"Corneal Transplantation","enrollment":60},{"nctId":"NCT00892918","phase":"NA","title":"Effect of Moxifloxacin Versus Gatifloxacin on Corneal Epithelium Following Pterygium Excision","status":"UNKNOWN","sponsor":"Meir Medical Center","startDate":"2009-06","conditions":"Primary Pterygium","enrollment":40},{"nctId":"NCT00703313","phase":"PHASE4","title":"Ocular Availability in Human Tears After Topical Administration of 1.5% Levofloxacin Compared to Active Comparators","status":"COMPLETED","sponsor":"Santen Inc.","startDate":"2008-05","conditions":"Healthy","enrollment":72},{"nctId":"NCT00630019","phase":"PHASE4","title":"Ocular Tissue Levels of 1.5% Levofloxacin Ophthalmic Solution Compared to an Active Comparator","status":"COMPLETED","sponsor":"Santen Inc.","startDate":"2008-02","conditions":"Cataract","enrollment":96},{"nctId":"NCT00335088","phase":"PHASE3","title":"Local Moxifloxacin and Povidone Iodine Versus Povidone Iodine Alone as a Prophylaxis Before Eye Operations","status":"UNKNOWN","sponsor":"HaEmek Medical Center, Israel","startDate":"2006-06","conditions":"Eye Infections","enrollment":500},{"nctId":"NCT00347828","phase":"PHASE4","title":"Effectiveness Study of Zymar Versus Vigamox for Preoperative Sterilization of the Ocular Surface After Loading Dose","status":"UNKNOWN","sponsor":"Ophthalmic Consultants of Boston","startDate":"2006-06","conditions":"Eye Infection, Infection","enrollment":40}],"_emaApprovals":[],"_faersSignals":[{"count":4,"reaction":"EYE PAIN"},{"count":2,"reaction":"EYE IRRITATION"},{"count":2,"reaction":"OCULAR HYPERAEMIA"},{"count":2,"reaction":"PRODUCT QUALITY ISSUE"},{"count":1,"reaction":"CHEST DISCOMFORT"},{"count":1,"reaction":"CONTRAINDICATED PRODUCT ADMINISTERED"},{"count":1,"reaction":"CORNEAL ABRASION"},{"count":1,"reaction":"CORNEAL INFECTION"},{"count":1,"reaction":"DRUG ADMINISTRATION ERROR"},{"count":1,"reaction":"DRY EYE"}],"_approvalHistory":[],"publicationCount":9,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Moxifloxacin Hydrochloride, Ophthalmic","genericName":"Moxifloxacin Hydrochloride, Ophthalmic","companyName":"Laboratorios Sophia S.A de C.V.","companyId":"laboratorios-sophia-s-a-de-c-v","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Moxifloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription in susceptible microorganisms. Used for Bacterial conjunctivitis, Bacterial keratitis, Bacterial corneal ulcer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}